Fairvalue-Calculator Fairvalue-Calculator
EN DE

ABVC BioPharma, Inc (ABVC) Fair Value & Analysis

Healthcare · US · Market cap $35.9M

Price$1.31
Fair Value$1.92
Upside+46.6%
Quality80/100
Evidence: Low Range $1.44 – $2.40

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ABVC BioPharma, Inc (ABVC) currently trades at $1.31, while our model-based Fair Value estimate is $1.92 — implying the stock looks roughly 46.6% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is ABVC BioPharma, Inc (ABVC) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.92 versus a price of $1.31 — about +47% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ABVC?
Our 21-model fair value for ABVC BioPharma, Inc is $1.92 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.31.
What is the quality score of ABVC?
ABVC BioPharma, Inc has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.